Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3012)	7/26/2010 12:07:34 PM
From: Jibacoa	Respond to of 3722

AVNR is still up 3.03% on volume almost half its ADV bigcharts.marketwatch.com AVNR had some positive comments in Seeking Alpha and the Motley Fool.<g> Its SPA with the FDA has an emphasis on safety and tolerability to go along with the efficacy data that was clearly demonstrated in the recent STAR trial. The stock is up for 3rd day on a roll. It now faces resistance at the $3.50 level before it can test its July 12 H at $3.73 <g> bigcharts.marketwatch.com AVNR has NLTD, the insiders reportedly hold > 15% of the shrs, but have been persistent sellers lately. However, it seems that with the results of Zenvia on the STAR trial, the drug has a good chance to get an OK from the FDA in October. The ACTAY has been increased to $8.38 On a close above its July 2009 of $4.06 the stock has further room to run.<g> On that basis the R/R doesn't look bad.<g> bigcharts.marketwatch.com Bernard